Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum
暂无分享,去创建一个
B. Pradines | M. Gendrot | M. Madamet | R. Amalvict | Océane Delandre | Isabelle Fonta | J. Mosnier | N. Benoît | N. Gomez | Marylin Madamet | Mathieu Gendrot
[1] E. Schmitt,et al. High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine , 2021, The Journal of infectious diseases.
[2] L. Mutesa,et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. , 2021, The Lancet. Infectious diseases.
[3] B. Pradines,et al. Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum , 2021, Pharmaceuticals.
[4] F. Mockenhaupt,et al. Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda , 2021, Emerging infectious diseases.
[5] D. Hartl,et al. Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum , 2020, PLoS genetics.
[6] B. Pradines,et al. Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal. , 2020, International journal of antimicrobial agents.
[7] D. Fidock,et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda , 2020, Nature Medicine.
[8] J. Gomis,et al. Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal , 2020, Scientific Reports.
[9] U. Morris,et al. Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018–2019 , 2020, Malaria Journal.
[10] B. Pradines,et al. Changes in malaria epidemiology in France and worldwide, 2000-2015. , 2020, Medecine et maladies infectieuses.
[11] B. Pradines,et al. Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa? , 2019, Malaria Journal.
[12] P. Kremsner,et al. An alternative dogma on reduced artemisinin susceptibility: A new shadow from east to west , 2019, Proceedings of the National Academy of Sciences.
[13] R. Piarroux,et al. Epidemiologic Trends in Malaria Incidence Among Travelers Returning to Metropolitan France, 1996-2016 , 2019, JAMA network open.
[14] L. Ayong,et al. Current Situation of Malaria in Africa. , 2019, Methods in molecular biology.
[15] D. Hartl,et al. Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility , 2018, Proceedings of the National Academy of Sciences.
[16] V. Vullo,et al. Dihydroartemisinin–piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia , 2018, Infection.
[17] P. Bastien,et al. The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates , 2018, Malaria Journal.
[18] R. Piarroux,et al. Plasmodium falciparum Recrudescence Two Years after Treatment of an Uncomplicated Infection without Return to an Area Where Malaria Is Endemic , 2017, Antimicrobial Agents and Chemotherapy.
[19] B. Pradines,et al. Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. , 2017, International journal of antimicrobial agents.
[20] Mehul Dhorda,et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study , 2017, The Lancet. Infectious diseases.
[21] P. Ringwald,et al. Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015 , 2017, Malaria Journal.
[22] Dhruviben S. Patel,et al. Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015 , 2017, Malaria Journal.
[23] M. Berriman,et al. pfk13-Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom , 2017, Antimicrobial Agents and Chemotherapy.
[24] F. Gobbi,et al. Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia , 2016, Malaria Journal.
[25] J. Ndiaye,et al. West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia. , 2016, The American journal of tropical medicine and hygiene.
[26] F. Frischknecht,et al. The Actin Filament-Binding Protein Coronin Regulates Motility in Plasmodium Sporozoites , 2016, PLoS pathogens.
[27] C. Rogier,et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.
[28] F. Frischknecht,et al. Plasmodium falciparum coronin organizes arrays of parallel actin filaments potentially guiding directional motility in invasive malaria parasites , 2015, Malaria Journal.
[29] S. Briolant,et al. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine , 2015, Malaria Journal.
[30] D. Kwiatkowski,et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.
[31] B. Genton,et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.
[32] S. Briolant,et al. Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests , 2013, Malaria Journal.
[33] F. Nosten,et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.
[34] B. Pradines,et al. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia , 2011, Malaria Journal.
[35] Organización Mundial de la Salud. Guidelines for the treatment of malaria , 2010 .
[36] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.